【TaiGen】The Company's Board of Directors Resolves to Approve the 2026 Q1 Consolidated Financial Report
Key facts
- 【TaiGen】The Company's Board of Directors Resolves to Approve the 2026 Q1 Consolidated Financial Report
- TaiGen Biotechnology announced that its Board of Directors approved the 2026 Q1 consolidated financial report. The company reported revenue of NT$172,891 thousand, a pre-tax net loss of NT$26,215 thousand, and basic EPS of -0.45 NTD.
- Source: PR Times
- Date: May 7, 2026
Direct answer
TaiGen Biotechnology announced that its Board of Directors approved the 2026 Q1 consolidated financial report. The company reported revenue of NT$172,891 thousand, a pre-tax net loss of NT$26,215 thousand, and basic EPS of -0.45 NTD.
- Citation
- 【TaiGen】The Company's Board of Directors Resolves to Approve the 2026 Q1 Consolidated Financial Report (May 7, 2026), PR Times
- Source
- PR Times
- Date
- May 7, 2026
TaiGen Biotechnology announced that its Board of Directors approved the 2026 Q1 consolidated financial report. The company reported revenue of NT$172,891 thousand, a pre-tax net loss of NT$26,215 thousand, and basic EPS of -0.45 NTD.
📋 Article Processing Timeline
- 📰 Published: May 7, 2026 at 09:00
- 🔍 Collected: May 8, 2026 at 08:00 (23h 0m after Published)
- 🤖 AI Analyzed: May 8, 2026 at 08:05 (5 min after Collected)
2.Date of approval by the Audit Committee:2026/05/07
3.Reporting period of financial report or unaudited financial information:
From 2026/01/01 to 2026/03/31
4.Cumulative operating revenue from January 1 to the current period (NT$ thousands):172891
5.Cumulative operating gross profit (gross loss) from January 1 to the current period (NT$ thousands):77192
6.Cumulative operating income (loss) from January 1 to the current period (NT$ thousands):-27821
7.Cumulative pre-tax net income (net loss) from January 1 to the current period (NT$ thousands):-26215
8.Cumulative net income (net loss) for the current period from January 1 to the current period (NT$ thousands):-26340
9.Cumulative net income (loss) attributable to owners of the parent from January 1 to the current period (NT$ thousands):-26340
10.Cumulative basic earnings (loss) per share from January 1 to the current period (NTD):-0.45
11.Total assets at period-end (NT$ thousands):1270178
12.Total liabilities at period-end (NT$ thousands):160178
13.Equity attributable to owners of the parent at period-end (NT$ thousands):1110000
14.Other matters that need to be specified:None
FAQ
What are the key facts in this article?
TaiGen Biotechnology announced that its Board of Directors approved the 2026 Q1 consolidated financial report. The company reported revenue of NT$172,891 thousand, a pre-tax net loss of NT$26,215 thousand, and basic EPS of -0.45 NTD.
What is the direct answer?
TaiGen Biotechnology announced that its Board of Directors approved the 2026 Q1 consolidated financial report. The company reported revenue of NT$172,891 thousand, a pre-tax net loss of NT$26,215 thousand, and basic EPS of -0.45 NTD.
What is the source and date?
PR Times: https://mops.twse.com.tw/material/twse-4169-2026-05-07-f2172a6f | May 7, 2026